Engineered T Cells Conditional Receptor Expression via Endogenous Locus Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for engineering T cells to express recombinant receptors, such as CARs, for cancer and other disease treatments face challenges in achieving controlled and specific expression to avoid targeting healthy cells and minimizing unwanted side effects.
Innovation Solution
The development of engineered T cells with a modified T cell stimulation-associated locus that conditionally expresses a recombinant receptor, where the expression is induced by an activation signal and downregulated in its absence, using targeted integration of transgenes via homology-directed repair (HDR) to link the recombinant receptor to endogenous transcriptional regulatory elements, reducing antigen-independent signaling and minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are engineered to constitutively express recombinant receptors, then therapeutic efficacy is improved, but off-target effects and damage to healthy cells increase
Solution Approach 1:
The patent employs dynamic control of recombinant receptor expression by linking the transgene to endogenous T cell stimulation-associated loci. The receptor expression level changes dynamically based on T cell activation state, being low in resting cells and high in activated cells, thereby resolving the contradiction between maintaining therapeutic efficacy and minimizing off-target effects on healthy cells.
Solution Approach 2:
The invention changes the expression parameter of the recombinant receptor from constitutive to conditional by utilizing endogenous regulatory elements. This parameter change allows the system to adapt expression levels according to physiological conditions, improving the therapeutic index by reducing exposure of healthy cells to the receptor while maintaining efficacy in activated therapeutic cells.
2Reliability
If T cells are engineered to constitutively express recombinant receptors, then antigen recognition capability is improved, but antigen-independent signaling increases
Solution Approach 1:
The patent creates a dynamic expression system where recombinant receptor levels are coupled to T cell activation status. Resting cells exhibit minimal receptor expression and thus minimal antigen-independent signaling, while activated cells express high levels for effective antigen recognition. This dynamic regulation resolves the contradiction between these two requirements.
Solution Approach 2:
The invention uses endogenous T cell stimulation-associated loci as intermediaries to control transgene expression. These loci act as natural sensors of T cell activation state, mediating the relationship between cellular activation and receptor expression, thereby preventing inappropriate antigen-independent signaling while preserving antigen recognition capability when needed.
3Ease of manufacture
If conventional integration methods are used to insert transgenes, then manufacturing simplicity is maintained, but integration precision and control over expression regulation deteriorate
Solution Approach 1:
The patent employs homology-directed repair (HDR) which requires preliminary design of homology arms flanking the transgene. This preliminary action enables precise targeting to specific genomic loci while maintaining relatively simple manufacturing workflows. The pre-designed homology arms guide precise integration without requiring complex multi-step procedures, thus resolving the contradiction between manufacturing simplicity and integration precision.
Solution Approach 2:
The invention replaces conventional random integration mechanisms with a targeted integration system based on HDR. This substitution uses molecular recognition (homology arm pairing) instead of random insertion, achieving precise integration at predetermined genomic locations while maintaining manufacturing feasibility through established gene editing workflows.
4Object-affected harmful factors
If transient expression of recombinant receptors is achieved, then damage to healthy cells is minimized, but duration of therapeutic action is reduced
Solution Approach 1:
The patent implements periodic or conditional expression of recombinant receptors tied to T cell activation cycles. The receptor is expressed transiently during activation periods when therapeutic action is needed, and downregulated during resting periods to minimize damage to healthy cells. This periodic pattern resolves the contradiction between minimizing harm and maintaining adequate duration of therapeutic effect.
Solution Approach 2:
The invention changes the temporal parameter of receptor expression from permanent to transient by coupling it to activation-dependent regulatory elements. This parameter change allows the system to provide therapeutic action during activation phases while minimizing exposure during non-therapeutic phases, effectively balancing duration of action with reduction of harmful effects on healthy cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for transient and specific expression of the recombinant receptor in response to activation signals, enhancing the therapeutic efficacy of T cell therapies while minimizing damage to healthy cells by controlling the duration and level of receptor expression.
Implementation Method 1
the endogenous transcriptional regulatory element induces or upregulates expression of the operably linked transgene following a simulation or activation signal in the T cell
Implementation Method 2
using targeted integration of transgenes via homology-directed repair (HDR) to link the recombinant receptor to endogenous transcriptional regulatory elements
Data Source
AI summary
Provided are engineered T cells that contain a modified T cell stimulation-associated locus encoding a recombinant receptor or a portion thereof. In some aspects, the nucleic acid sequence encoding the recombinant receptor or a portion thereof is operably linked to an endogenous transcriptional regulatory element of the T cell stimulation-associated locus, in some cases, engineered by targeted integration. In some aspects, the engineered cells conditionally express the recombinant receptor, such as upon stimulation or activation signal in the T cell. Also disclosed are cell compositions, nucleic acids for engineering cells, and methods and articles of manufacture for producing the engineered cells. In some embodiments, the engineered cells can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.